Long-term treatment of evocalcet in hemodialysis patients with secondary hyperparathyroidism: a five-year prospective cohort study in 147 Japanese patients
Nobuo Nagano(Kirin (Japan)), Kyoko Ito, Tetsuya Ogawa(Nihon University), Masashi Yamaguchi(University of Miyazaki), Masaaki Miya(Hidaka Hospital), Yuji Katsuragi(Hidaka Hospital), Noriko Tamei(Hidaka Hospital), Takaaki Tsutsui(Hidaka Hospital), Shigeaki Muto(Jichi Medical University), Takayuki Ishikawa(Kobe City Medical Center General Hospital)
Cited by 2
Related Papers
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
|Nature Medicine|2020|633
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
|The Lancet Haematology|2019|247
Left Ventricular Hypertrophy Is Associated with Arterial Stiffness and Vascular Calcification in Hemodialysis Patients
|Hypertension Research|2004|161